May 11, 2016
Meiji Seika Pharma said on May 10 that it has terminated the development of ME3113 (udenafil), a drug candidate for benign prostatic hyperplasia (BPH), based on the results of its PII study. Udenafil is a phosphodiesterase-5 (PDE5) inhibitor originated by...read more